Table 2.
Summary of results of clinical trials of decitabine in MDS
View large
Summary of results of clinical trials of decitabine in MDS

CMML indicates chronic myelomonocytic leukemia; ND, not described; PR, partial remission; HI, hematologic improvement; ORR, overall response rate (CR + PR + HI); and Cyto, cytogenetic response.

*Dysplasia possible.

†IWG 2000 criteria.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal